## Franck Lebrin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3185549/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Imaging the Renal Microcirculation in Cell Therapy. Cells, 2021, 10, 1087.	4.1	5
2	Thresholds of Endoglin Expression in Endothelial Cells Explains Vascular Etiology in Hereditary Hemorrhagic Telangiectasia Type 1. International Journal of Molecular Sciences, 2021, 22, 8948.	4.1	5
3	Decreased Expression of Vascular Endothelial Growth Factor Receptor 1 Contributes to the Pathogenesis of Hereditary Hemorrhagic Telangiectasia Type 2. Circulation, 2018, 138, 2698-2712.	1.6	26
4	A New Wnt1-CRE TomatoRosa Embryonic Stem Cell Line: A Tool for Studying Neural Crest Cell Integration Capacity. Stem Cells and Development, 2017, 26, 1682-1694.	2.1	1
5	Interaction Between ALK1 Signaling and Connexin40 in the Development of Arteriovenous Malformations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 707-717.	2.4	22
6	Pericytes as targets in hereditary hemorrhagic telangiectasia. Frontiers in Genetics, 2015, 6, 37.	2.3	42
7	ENDOGLIN Is Dispensable for Vasculogenesis, but Required for Vascular Endothelial Growth Factor-Induced Angiogenesis. PLoS ONE, 2014, 9, e86273.	2.5	59
8	Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nature Medicine, 2010, 16, 420-428.	30.7	312
9	Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction. EMBO Journal, 2004, 23, 4018-4028.	7.8	592
10	Controlling the Angiogenic Switch. Trends in Cardiovascular Medicine, 2003, 13, 301-307.	4.9	302